Delcath Systems, Inc. (DCTH)

Delcath Systems' stock price has declined approximately 44.98% over the past year. In Q3 2025, EPS was $0.02, surpassing expectations by 140.00%. Preliminary results for 2025 project total revenue of $85.2 million, including $78.8 million from HEPZATO KIT. Insider trading shows a net buy value of $137,040.54 in the last 90 days. A share repurchase program of $25.0 million was authorized in November 2025.

The provided information does not explicitly indicate demand seasonality for Delcath Systems' products and services. However, the projected 150% increase in total HEPZATO treatment volume in 2025 over 2024 suggests a growing demand for their liver cancer treatments rather than seasonal fluctuations.

Delcath Systems, Inc. is an interventional oncology company focused on treating liver cancers in the United States and Europe. They operate in the Health Care sector, producing products like HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System, designed to deliver chemotherapy directly to the liver while minimizing systemic exposure.

Delcath Systems, Inc. conducts its business operations and markets its products in the United States and Europe.

Delcath Systems has maintained a positive brand reputation, marked by 140% growth in HEPZATO procedure volume in 2025 compared to 2024. Positive results from the Phase 2 CHOPIN trial were presented at the 2025 European Society of Medical Oncology Annual Congress. Recent publications have highlighted the application, enhanced outcomes, and efficacy of percutaneous hepatic perfusion in managing metastatic uveal melanoma.

Delcath Systems' ownership is a mix of institutional (45.51% to 52.01%), insider (32.87% to 30.89%), and public investors (21.62% to 28.25%). Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., and Vanguard Group Inc. Key individual insider owners include Steven A J Salamon, Gil Aharon, and Gerard J Michel.